An E-platform for Learners

Day: November 20, 2025

Merck to Acquire Cidara Therapeutics for $9.2 Billion to Bolster Influenza Prevention Pipeline Pharm'Up

Pharm'Up

Merck to Acquire Cidara Therapeutics for $9.2 Billion to Bolster Influenza Prevention Pipeline

Pharm'Up

Merck (known as MSD outside the U.S. and Canada) and Cidara Therapeutics, Inc., a biotechnology company specializing...

Novartis’s GanLum Achieves 97.4% Cure Rate in Landmark Phase III Malaria Trial Amid Rising Drug Resistance Pharm'Up

Pharm'Up

Novartis’s GanLum Achieves 97.4% Cure Rate in Landmark Phase III Malaria Trial Amid Rising Drug Resistance

Pharm'Up

Novartis, in partnership with Medicines for Malaria Venture (MMV), has announced compelling Phase III results for their...

Lupin’s Nagpur Unit-1 Passes U.S. FDA Pre-Approval Inspection with Flawless Record Pharm'Up

Pharm'Up

Lupin’s Nagpur Unit-1 Passes U.S. FDA Pre-Approval Inspection with Flawless Record

Pharm'Up

Lupin Limited, a leading global pharmaceutical company, has successfully completed a product-specific Pre-Approval Inspection (PAI) conducted by...

Sandoz Launches TYRUKO® in US A Game-Changer as First Multiple Sclerosis Biosimilar Pharm'Up

Pharm'Up

Sandoz Launches TYRUKO® in US A Game-Changer as First Multiple Sclerosis Biosimilar

Pharm'Up

Sandoz, a global leader in affordable generic and biosimilar medicines, has announced the availability of TYRUKO® (natalizumab-sztn)...

AstraZeneca and Sun Pharma Partner to Broaden Access to Hyperkalaemia Treatment in India Pharm'Up

Pharm'Up

AstraZeneca and Sun Pharma Partner to Broaden Access to Hyperkalaemia Treatment in India

Pharm'Up

AstraZeneca Pharma India Limited and Sun Pharmaceutical Industries Limited have announced a second exclusive brand partnership in...

Utreglutide (GL0034) Shows Potent Weight Loss and Significant Liver-Fat Reduction in Mid-Stage Trials Pharm'Up

Pharm'Up

Utreglutide (GL0034) Shows Potent Weight Loss and Significant Liver-Fat Reduction in Mid-Stage Trials

Pharm'Up

Sun Pharmaceutical Industries Ltd. has announced highly promising clinical results for its novel investigational once-weekly GLP-1 receptor...